Detalhe da pesquisa
1.
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Blood
; 139(19): 2931-2941, 2022 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35007321
2.
Gating Harmonization Guidelines for Intracellular Cytokine Staining Validated in Second International Multiconsortia Proficiency Panel Conducted by Cancer Immunotherapy Consortium (CIC/CRI).
Cytometry A
; 99(1): 107-116, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33090656
3.
An evaluation of the practice of electroconvulsive therapy (ECT) in a Victorian health service before and after the Mental Health Act 2014.
Australas Psychiatry
; 28(3): 279-285, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32019352
4.
Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study.
Biol Blood Marrow Transplant
; 25(2): 256-264, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30205231
5.
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
Blood
; 124(7): 1183-91, 2014 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24963042
6.
A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI).
Cytometry A
; 83(8): 728-38, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23788464
7.
Single versus multiple primary melanomas: old questions and new answers.
Cancer
; 118(17): 4184-92, 2012 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22246969
8.
A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols.
J Transl Med
; 9: 108, 2011 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-21745365
9.
Impact of socioeconomic status and sociodemographic factors on melanoma presentation among ethnic minorities.
J Community Health
; 36(3): 461-8, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21080042
10.
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.
Blood Adv
; 2(24): 3572-3580, 2018 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-30563881
11.
Guidelines for the automated evaluation of Elispot assays.
Nat Protoc
; 10(7): 1098-115, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26110715
12.
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.
Leuk Lymphoma
; 56(9): 2543-51, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25563429
13.
Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis.
Leuk Lymphoma
; 60(5): 1343-1345, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30668266
14.
Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories.
Methods Mol Biol
; 792: 185-96, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-21956511
15.
Head and neck radiotherapy compliance in an underserved patient population.
Laryngoscope
; 120(7): 1336-41, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20564718